ReShape Lifesciences Inc
Research ReShape Lifesciences Inc (HIND) on Bullrun: market cap USD 15.65M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHIND
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 15.65M
- Financial periodQ1 2026
- RevenueUSD 31.59K
- Net income-USD 962.91K
- Free cash flow-USD 4.98M
- Gross margin52.7%
Valuation Snapshot
latest market cap is USD 15.65M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 319.71K | -USD 10.26M | n/a | 68.4% | -4.86 | USD 4.98M | USD 31.26K | USD 3.76M |
| FY2024 | USD 8.01M | -USD 1.45M | n/a | 2.4% | -6001.39 | USD 101.90K | USD 811.00K | -USD 4.39M |
| FY2023 | USD 8.68M | -USD 11.39M | -USD 17.00M | 63.9% | -110.87 | USD 4.46M | n/a | -USD 6.17M |
| FY2022 | USD 11.24M | -USD 46.21M | -USD 22.03M | 60.5% | -108.9 | USD 3.86M | n/a | USD 3.66M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 15.65M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 20.36M | 0.1 | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.26M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.64M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.91M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 47.56M | n/a | n/a | n/a |
About ReShape Lifesciences Inc
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ReShape Lifesciences Inc's market cap?
ReShape Lifesciences Inc's market capitalization is USD 15.65M.
What does ReShape Lifesciences Inc do?
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis.